Home/Pipeline/Glucose-Responsive Insulin Receptor Agonist

Glucose-Responsive Insulin Receptor Agonist

Diabetes

Pre-clinical (integrated into Lilly pipeline)Active

Key Facts

Indication

Diabetes

Phase

Pre-clinical (integrated into Lilly pipeline)

Status

Active

Company

Protomer Technologies

About Protomer Technologies

Protomer Technologies is a biotech innovator developing 'smart' therapeutics that can sense and respond to molecular signals in the body, such as glucose. Its core asset is the MEPS platform, a chemical biology-based protein engineering technology used to create conditionally active drugs. Acquired by Eli Lilly in 2021, Protomer operates as an agile subsidiary, with its lead program, a glucose-responsive insulin, now integrated into Lilly's pipeline. The company aims to widen the therapeutic window by creating medicines that are potent only when and where needed.

View full company profile

Therapeutic Areas

Metabolic Disease

Other Diabetes Drugs

Drug	Company	Phase	Status
AdOral® Insulin	Adocia	Preclinical	Platform Development
Oral Insulin	Premas Biotech	Phase 3	Active
PRX-3140	Nanopharmaceutics	Clinical	Active
Insulin Program	Biolingus	Pre-clinical	Active
Insulin Aspart Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Glargine Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Lispro Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Liraglutide Injection	Meitheal Pharmaceuticals	Approved	Active
Diabetes Clinical Trials	DM Clinical Research	Not Specified	Active
Diabetes Therapeutic	Housey Pharmaceutical Research Laboratories	Not specified	Active
Diabetes Research	Evidation Health	Research	Active
Injectable HDV-Rapid Acting Insulin (Open Label, MoA)	Diasome Pharmaceuticals	Phase 2	Active